Detalhe da pesquisa
1.
In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system.
Nature
; 516(7531): 423-7, 2014 Dec 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-25337876
2.
The E3 ubiquitin ligase MID1/TRIM18 promotes atypical ubiquitination of the BRCA2-associated factor 35, BRAF35.
Biochim Biophys Acta Mol Cell Res
; 1864(10): 1844-1854, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28760657
3.
Corrigendum: In vivo engineering of oncogenic chromosomal rearrangements with the CRISPR/Cas9 system.
Nature
; 524(7566): 502, 2015 Aug 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-26106864
4.
Bcl-2 associated athanogene 5 (Bag5) is overexpressed in prostate cancer and inhibits ER-stress induced apoptosis.
BMC Cancer
; 13: 96, 2013 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23448667
5.
Enhanced inhibition of prostate tumor growth by dual targeting the androgen receptor and the regulatory subunit type iα of protein kinase a in vivo.
Int J Mol Sci
; 14(6): 11942-62, 2013 Jun 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-23736698
6.
Applications of CRISPR-Cas9 for advancing precision medicine in oncology: from target discovery to disease modeling.
Front Genet
; 14: 1273994, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37908590
7.
SHP2: A Pleiotropic Target at the Interface of Cancer and Its Microenvironment.
Cancer Discov
; 13(11): 2339-2355, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37682219
8.
Bridging the gap between tumor-on-chip and clinics: a systematic review of 15 years of studies.
Lab Chip
; 23(18): 3906-3935, 2023 09 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37592893
9.
SALL4B, not targeted by IMiD, is important for SALL4-mediated tumorigenesis.
bioRxiv
; 2023 Jul 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37461690
10.
Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy.
Cancer Res Commun
; 3(7): 1378-1396, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37520743
11.
Identification of GDC-1971 (RLY-1971), a SHP2 Inhibitor Designed for the Treatment of Solid Tumors.
J Med Chem
; 66(19): 13384-13399, 2023 Oct 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37774359
12.
An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance.
Nat Cancer
; 4(6): 812-828, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37277530
13.
The CRISPR Revolution in the Drug Discovery Workflow: An Industry Perspective.
CRISPR J
; 5(5): 634-641, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35917561
14.
In Vivo Modeling of Tumor Heterogeneity for Immuno-Oncology Studies: Failures, Improvements, and Hopes.
Curr Protoc
; 2(3): e377, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35255200
15.
The anterior gradient 2 (AGR2) gene is overexpressed in prostate cancer and may be useful as a urine sediment marker for prostate cancer detection.
Prostate
; 71(6): 575-87, 2011 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-20945500
16.
SEMMs: Somatically Engineered Mouse Models. A New Tool for In Vivo Disease Modeling for Basic and Translational Research.
Front Oncol
; 11: 667189, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33968774
17.
Drug discovery oncology in a mouse: concepts, models and limitations.
Future Sci OA
; 7(8): FSO737, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-34295539
18.
Evaluation of two in vitro assays for tumorigenicity assessment of CRISPR-Cas9 genome-edited cells.
Mol Ther Methods Clin Dev
; 23: 241-253, 2021 Dec 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34703845
19.
Rlf-Mycl Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer.
Cancer Discov
; 11(12): 3214-3229, 2021 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34344693
20.
Somatic Engineering of Oncogenic Chromosomal Rearrangements: A Perspective.
Cancer Res
; 76(17): 4918-23, 2016 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27520450